Compare DTI & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DTI | VANI |
|---|---|---|
| Founded | 1984 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.7M | 81.2M |
| IPO Year | N/A | 2014 |
| Metric | DTI | VANI |
|---|---|---|
| Price | $2.97 | $1.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 106.5K | ★ 160.3K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $160,964,000.00 | N/A |
| Revenue This Year | $2.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.46 | N/A |
| 52 Week Low | $1.43 | $0.91 |
| 52 Week High | $3.82 | $1.92 |
| Indicator | DTI | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 58.03 | 58.72 |
| Support Level | $2.39 | $1.25 |
| Resistance Level | $2.82 | $1.54 |
| Average True Range (ATR) | 0.25 | 0.07 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 66.02 | 94.74 |
Drilling Tools International Corp manufactures, rents, inspects, and refurbishes downhole drilling tools primarily to companies in the oil and natural gas industry for bottom hole assemblies used in onshore and offshore horizontal and directional drilling. The company's United States operations have locations in Texas, California, Louisiana, Oklahoma, Pennsylvania, North Dakota, New Mexico, Utah, and Wyoming. The company's single segment derives revenues from customers by providing oilfield equipment and services to operators in the oil and natural gas sectors.
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.